Tesla Inc (NASDAQ:TSLA) delivered 484,507 vehicles during the fourth quarter, topping analyst estimates of 473,253, the electric vehicle (EV) maker reported on Tuesday.
It delivered 461,538 Model 3 and Y vehicles and 22,969 other models during the last three months of the year.
Apple Inc (NASDAQ:AAPL, ETR:APC) shares fell 3.6% to close at $185.64 on Tuesday after analysts at Barclays downgraded the stock to ‘Underweight’ from ‘Neutral,’ citing disappointing demand for its iPhone 15.
Saying it was time to take a “breather,” the analysts also cut their target price for Apple to $160 from $161.
Small cap and mid cap biotech and speculative pharma stocks have a more constructive outlook heading into 2024, relative to previous years, but the idiosyncratic nature of the space continues to put a premium on stock picking, according to Bank of America analysts.
BofA analysts are encouraged by sector fundamentals, including research and development (R&D) output and external demand for biotech innovation as measured by merger and acquisition (M&A) trends.
Voyager Therapeutics’ announcement that it has entered into an additional up to $1.2 billion collaboration with Novartis AG (ADR) (NYSE:NVS) for its TRACER capsids to develop potential gene therapies for Huntington’s disease and spinal muscular atrophy has Baird analysts positive on Voyager’s long-term outlook.
“Moving forward, we continue to be encouraged by high level of partnership interest in TRACER and maintain positive on Voyager shares as we look ahead to what are likely to be transformative years for the company,” the analysts wrote in a note to clients.
Doximity Inc is well-positioned to meet and exceed expectations for fiscal 2024 after the online networking service for medical professionals cut its guidance and messaged slower growth, according to analysts at Bank of America.
With "no more shoes to drop," the analysts have upgraded the stock to 'Neutral' from 'Underperform' and lifted their price objective to $29 from $21.
CVS Health Corp (NYSE:CVS) has two things it didn't have during the past few years: a clear path to accelerating earnings growth; and appropriately reset expectations, according to Bank of America analysts.
In an update to clients, the analysts noted the healthcare company’s earnings per share (EPS) targets of at least $8.50 in 2024 and 6% growth in 2025 are more than achievable.
Citius Pharmaceuticals is positioned for a strong 2024 with more than $26 million in cash and a Phase 3 trial that analysts at Dawson James are bullish on.
The company spent $36.7 million in operating expenses last year and ended 2023 2ith closed the year with $26.5 million in cash and equivalents, according to its fourth-quarter results.
There’s more than three-times upside to Union Jack Oil PLC (AIM:UJO)'s stock market valuation, that’s according to City broker SP Angel which today repeats a ‘buy’ recommendation for the British small-cap oil share.
Analyst David Mirzai said Union Jack, which is the largest stakeholder in Lincolnshire’s Wressle field, gives investors exposure to an unhedged portfolio of oil and gas production that generates free cash flow for reinvestment and shareholder returns.
Analysts believe hVIVO PLC (AIM:HVO), the scientific trials company, is in a strong position to win additional contracts after sealing a £6.3 million deal to research treating the common cold.
hVIVO will conduct the research using the human challenge study model for an unnamed biotechnology firm.
2024 is the year of the dragon in the Chinese Zodiac.
Similarly, there’s a fire inside the technology sector in the form of artificial intelligence (AI) and its flames are growing ever larger.
Plexus Holdings PLC (AIM:POS) shares jumped 10% then fell into the red after it announced a new, expanded IP licence agreement with SLB (previously Schlumberger) replacing the previous surface production wellhead licence agreement with Cameron (an SLB company) for a cash consideration of US$5.2 million.
The fact that the new licence agreement is royalty-free may have led to the swing in the shares, but broker Cavendish pointed out that Plexus had moved its focus away from the larger-volume, lower-cost surface production wellhead market.